OR WAIT null SECS
Editor of Pharmaceutical Technology Europe
As the RNA therapeutic market grows, contract manufacturing services for GMP-grade RNA are in demand and expected to continue on an upward trajectory.
Since the commercialization of an antisense oligonucleotide and subsequent RNA aptamer therapies in the late 1990s and early 2000s, respectively (1), a diverse set of RNA-based drugs that tackle wide ranging therapeutic needs have emerged in development. Most recently, two messenger RNA vaccines for COVID-19 have received emergency use approval by global regulatory bodies, representing a milestone success, according to topical commentary (2).
The successes of such therapies are being reflected in the potential growth of the RNA therapeutics market, which is expected to be strong in the near future with some market analysts estimating its worth at $2612.11 million by 2025 (3). Inevitably, market growth is spurred by an increase in demand, which in turn is giving rise to more opportunities for contract manufacturing organizations to service the sector.
To discuss RNA contract manufacturing services in more detail, BioPharm International spoke with David Ricketts, director of Business Development for Manufacturing Services, and Bernard Sagaert, chief operational officer, both at eTheRNA immunotherapies NV—a company that extended its RNA contract manufacturing services in November 2020 to meet growing demand (4).
Felicity Thomas is the European editor for BioPharm International.
eBook: Partnerships for Outsourcing, May 2021
When referring to this article, please cite it as author, “RNA’s Expanding Horizons,” BioPharm International Partnerships for Outsourcing eBook (May 2021).